Dr Reddys Laboratories Ltd’s Mixed Week: -1.31% Price Change Amid Technical Shifts

23 March 2026: Intraday Low Amid Broad Market Weakness

Dr Reddys Laboratories Ltd opened the week under pressure, closing at Rs.1,252.55, down 3.57% from the previous Friday’s close of Rs.1,298.95. The stock hit an intraday low of Rs.1,260.05, reflecting immediate selling interest amid a challenging market environment. The broader Sensex declined 3.13% to 32,377.87, weighed down by sectoral headwinds in Pharmaceuticals & Biotechnology, which fell 3.18% that day.

Despite the decline, Dr Reddys marginally outperformed its sector by 0.29%, showing relative resilience. Technical indicators were mixed, with the stock trading above its 50-day and 100-day moving averages but below shorter-term averages, signalling a cautious outlook. The Mojo Score at this point was 54.0, categorised as Hold, reflecting balanced fundamentals but short-term technical weakness.

24 March 2026: Downgrade to Sell Amid Technical and Financial Weakness

On 24 March, MarketsMOJO downgraded Dr Reddys Laboratories Ltd from Hold to Sell, citing deteriorating technical indicators and disappointing quarterly financial results. The Mojo Score dropped to 48.0, reflecting a shift to a mildly bearish technical stance. The stock closed marginally higher at Rs.1,259.60 (+0.56%), but the downgrade underscored concerns about near-term earnings momentum.

The company reported an 18.3% decline in Profit Before Tax (PBT) excluding other income to ₹1,274.40 crores for Q3 FY25-26, and a 16.2% drop in Profit After Tax (PAT) to ₹1,209.90 crores. Return on Capital Employed (ROCE) was a subdued 18.75% for the half-year, signalling reduced capital efficiency. Despite these setbacks, Dr Reddys maintains strong fundamentals, including a low debt-to-equity ratio of 0.01 and a 15.78% average Return on Equity (ROE).

25 March 2026: Intraday High and Positive Momentum

Dr Reddys Laboratories Ltd rebounded strongly on 25 March, surging 3.29% intraday to a high of Rs.1,303.15 and closing at Rs.1,301.90 (+3.36%). This marked the second consecutive day of gains, with the stock appreciating 3.84% over two sessions. The rally outpaced the Pharmaceuticals & Biotechnology sector’s 2.21% gain and the Sensex’s 1.93% rise to 33,645.89.

The stock traded above all key moving averages, signalling robust short- to medium-term momentum. Technical indicators such as the weekly MACD remained bullish, although monthly signals were mildly bearish, reflecting some caution. The surge was supported by active trading volume and broad market optimism, despite the recent downgrade to Sell.

27 March 2026: Mixed Technical Signals Amid Sideways Momentum

On the final trading day of the week, Dr Reddys Laboratories Ltd closed at Rs.1,281.95, down 1.53% from the previous close. The stock exhibited a shift from mildly bearish to sideways technical momentum, with mixed signals across key indicators. The weekly MACD and Bollinger Bands suggested strengthening momentum, while monthly MACD and daily moving averages remained bearish.

Volume trends showed mild bullishness on the weekly chart but no clear monthly direction. The Relative Strength Index (RSI) hovered in neutral territory, indicating a balanced tug-of-war between buyers and sellers. The stock’s Mojo Score remained at 48.0 with a Sell grade, reflecting ongoing caution despite recent price gains.

Daily Price Comparison: Dr Reddys Laboratories Ltd vs Sensex

Key Takeaways

Positive Signals: Despite a challenging week, Dr Reddys Laboratories Ltd outperformed the Sensex by 0.15% over the week, closing at Rs.1,281.95. The stock demonstrated resilience with a strong intraday high of Rs.1,303.15 on 25 March and maintained technical support above key moving averages during the rally. Long-term fundamentals remain robust, with low leverage and solid profitability metrics.

Cautionary Signals: The downgrade to a Sell rating by MarketsMOJO reflects deteriorating technical momentum and disappointing quarterly earnings, with PBT and PAT declining over 16%. Mixed technical indicators, including bearish daily moving averages and mildly bearish monthly MACD, suggest near-term volatility and uncertainty. The elevated PEG ratio of 5.2 signals valuation concerns relative to earnings growth.

Overall, the stock is navigating a complex technical landscape with short-term bearishness tempered by medium-term bullish hints. Investors should monitor key support levels near Rs.1,260 and resistance around Rs.1,375 for directional cues.

Conclusion

Dr Reddys Laboratories Ltd’s week was marked by volatility and mixed signals. The stock’s 1.31% weekly decline was modest compared to the Sensex’s 1.46% fall, reflecting relative strength amid sectoral and market pressures. The downgrade to Sell highlights near-term risks from earnings softness and technical deterioration, despite the company’s strong long-term fundamentals and conservative balance sheet.

Technical momentum remains in flux, with bullish weekly indicators offset by bearish monthly trends and daily averages. The stock’s ability to hold above key support levels will be critical in determining its next phase. For now, cautious monitoring is warranted as Dr Reddys Laboratories navigates this transitional period within a challenging market environment.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →